Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyCommunity Health Plan Washington PGx Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedCommunity Health Plan WashingtonPolicy N/A

    Concert Genetic Testing: Toxicology and Pharmacogenetics (Version B)

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, example tests, and coding implications for pharmacogenetic and toxicology-related genetic tests used to assess drug response, toxicity, and metabolizer status for members of Community Health Plan Washington (Centene-affiliated plans). Affects providers ordering or billing for pharmacogenetic and selected single-gene variant tests.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyConcert Genetic Testing: Toxicology and Pharmacogenetics (Version B)
    Policy CodePolicy N/A
    Change TypeMaterial updates to criteria, additions to coding table, FDA guidance incorporation
    Effective DateN/A
    Next Review DateN/A
    Key ActionOrder pharmacogenetic panels only when member meets criteria (age ≥18, specified diagnosis/treatment context, and the panel has demonstrated clinical validity).
    SourceLink
    POLICY UPDATE CHANGES

    Multiple definitions and criteria were updated across gene variant analyses and the policy reference table; language changed and additional genes/tests and CPT codes were added.

    FDA Table of Pharmacogenetic Associations recommendations were incorporated for multiple genes including HLA-B*15:02, HLA-B*57:01, TPMT/NUDT15, UGT1A1, UGT2B17, VKORC1, and NAT2.

    Multiple single-gene and panel pharmacogenetic criteria and definitions were updated (examples: UGT1A1, UGT2B17, VKORC1, DPYD, HLA variants, NAT2, TPMT, NUDT15, CYP family genes) and CPT codes 0423U, 0434U, 0437U, 0438U were added to the coding reference table.

    Pharmacogenetic panel testing criteria changed to require demonstrated clinical validity and added medically necessary panels and LCD-aligned indications (e.g., MDD, GAD) with age thresholds.

    Warfarin Sensitivity Analysis Panels: clinical criteria were added to allow coverage of small targeted panels for this indication.

    18+validated panels named
    4CPT codes added
    >=18age requirement
    MDD/GADdiagnosis-limited
    presentunsupported genes list
    multiplerevision entries

    Coverage Criteria for Pharmacogenetic and Toxicology Genetic Testing

    Pharmacogenetic testing coverage criteria and explanatory nodes

    Pharmacogenetic testing (single-gene and panel) coverage determinations are based on specific clinical indications, test validity, and applicable gene–drug management guidance. Tests not meeting the criteria below are considered investigational or not medically necessary.

    ALL of the following

    • Pharmacogenetic panel tests (as listed) are considered medically necessary only when ALL of the following are met:

      See enumerated list of covered panels below.

    • ALL of the following

      • Member is age 18 years or older.
      • Member is being considered for, or is currently being treated with, one or more specific medication(s) related to their diagnosis that are known to have a gene–drug interaction.
      • The requested pharmacogenetic panel test has proven clinical validity as demonstrated through independent evaluation from a recognized third‑party source (including but not limited to MolDx, ECRI, Hayes, Optum Genomics, or FDA).

        Panels without demonstrated clinical validity are not covered.

      • The requested test is one of the following listed panels:
      • ANY of the following

        • GeneSight (Assurex Health): 0345U
        • Neuropharmagen (Precision Molecular Solutions): 81418
        • PGXPSYCH (PHD Laboratory LLC): 81418
        • Psychotropic Pharmacogenomics Gene Panel (Mayo): 81418
        • Focused Pharm Panel (Mayo): 0029U
        • IDgenetix (Castle): 0411U
        • Tempus nP (Tempus): 0419U

    ALL of the following

    • Covered clinical diagnoses for pharmacogenetic panel testing (panels listed above) must include ALL of the following:

      Panels are limited to the indications below.

    • ANY of the following

      • Major depressive disorder.
      • Generalized anxiety disorder.

    Coverage Criteria for Pharmacogenetic and Toxicology Genetic Testing

    Policy updates and rationale summary for pharmacogenetic coverage criteria changes.

    title
    Pharmacogenetic coverage criteria updates
    type":"criteria_group"}],
    id":"coverage-criteria","label":"COVERAGE CRITERIA","title":"Coverage Criteria for Pharmacogenetic and Toxicology Genetic Testing"} PMID:{
    _note":"end"}json_output_schema

    Coding and Billing References

    Example pharmacogenetic panel billing codesCPT
    81418Pharmacogenetic Panel Tests Validated Tests, COMMON BILLING CODES
    0345UGeneSight (Assurex Health) example PLA code
    0419UTempus nP example PLA code
    0029UFocused Pharm Panel (Mayo) example PLA code
    0411UIDgenetix example PLA code
    Examples of codes referenced for unsupported single-gene analysesmixedNot Covered
    0032UCOMT (listed as not supported)
    0031UCYP1A2 (listed as not supported)
    81479Miscellaneous/unlisted molecular pathology code referenced for several unsupported genes
    Examples of single-gene codes mentionedCPT | mixedNot Covered
    0032UCOMT (listed as not supported)
    0031UCYP1A2 (listed as not supported)
    81479Unlisted molecular pathology procedure (used for several single-gene PGx tests listed as not supported)
    Newly added CPT/PLA codesCPT
    0423UAdded to policy coding reference table
    0434UAdded to policy coding reference table
    0437UAdded to policy coding reference table
    0438UAdded to policy coding reference table
    New CPT additionsCPT
    0423UCPT code added to policy coding reference table
    0434UCPT code added to policy coding reference table
    0437UCPT code added to policy coding reference table
    0438UCPT code added to policy coding reference table
    Coding accuracy note
    Coding comprehensivenessCodes listed in this policy are not all-inclusive; inclusion or exclusion does not guarantee coverage—refer to current CPT manuals and professional coding guidance before claim submission.
    Claims submission guidanceProviders should reference the most up-to-date professional coding guidance and the Concert Platform for registered tests prior to submitting claims.
    Informational purposeCPT codes and descriptions included are for informational purposes only and are from the current manuals (copyright 2024 AMA).

    Provider Actions, Authorization, and Documentation Requirements

    Billing Rule

    Coding guidance and claims submission

    This clinical policy references Current Procedural Terminology (CPT®). CPT is a registered trademark of the American Medical Association. CPT codes and descriptions are provided for informational purposes only and do not guarantee coverage. Providers should reference the most up-to-date professional coding guidance prior to submission of claims. The tests, CPT codes, and ICD codes referenced in this policy are not comprehensive. Please see the Concert Platform for additional registered tests.

    • Providers must follow professional coding guidance when submitting claims.
    • Codes shown in this policy are informational only; inclusion or exclusion does not guarantee coverage.
    • See the Concert Platform for the list of registered tests and specific test coding.
    Prior Authorization

    Definitions and Terms Used in This Policy

    Pharmacogenetic panel tests
    DefinitionPharmacogenetic panel tests are multi-gene assays intended to detect variants associated with drug response or toxicity.
    Validated panels requirementRequested panels must be a listed validated test with proven clinical validity; named medically necessary panels include examples such as Focused Pharm Panel (0029U), Tempus nP (0419U), GeneSight (0345U), PGX/Comprehensive panels (81418).
    Age and indication limitsPanel testing criteria include age threshold (>=18 years) and indication alignment (e.g., major depressive disorder or generalized anxiety disorder) per LCD-based guidance.
    Medically necessary (definition)
    DefinitionMedically necessary: Testing that meets the related criteria outlined in this policy for member eligibility and clinical indications.
    Role in coverage decisions

    Background, Clinical Guidance, and References

    The policy references the FDA Table of Pharmacogenetic Associations as a key regulatory source that informs gene-drug management recommendations incorporated into coverage criteria. The FDA entries summarize clinically actionable gene-drug pairs and specify recommended management for affected subgroups — for example, the FDA recommends avoiding carbamazepine, and considering avoidance of fosphenytoin and phenytoin, in patients positive for HLA-B*15:02 due to increased risk of severe cutaneous reactions (SJS/TEN) [[54]].

    Similarly, the FDA guidance for HLA-B*57:01 indicates that abacavir should not be used in allele-positive patients because of hypersensitivity risk [[55]]. For thiopurine-related genes TPMT and NUDT15, the FDA recommends dose reductions for intermediate metabolizers and consideration of alternatives or substantial dose adjustments for poor metabolizers to mitigate myelosuppression risk; specific dosing details are referenced to FDA labeling [[57]].

    The FDA Table also provides gene-specific management for UGT family members and warfarin-related genes: for UGT1A1, poor metabolizers (e.g., *28/*28) may require reduced belinostat starting dose and modified irinotecan monitoring/dosing to reduce neutropenia risk [[59]]; for UGT2B17 (and CYP2C19 in the same entry) the FDA notes increased systemic concentrations with belzutifan in poor metabolizers and recommends monitoring for anemia and hypoxia [[60]].

    For warfarin pharmacogenetics the FDA entry describes that variants in CYP2C9, CYP4F2, and VKORC1 can alter dosage requirements and that initial dosing should account for clinical and genetic factors with ongoing INR monitoring and dose adjustment — a rationale the policy uses to support single-gene and small targeted panel coverage for warfarin sensitivity when clinical criteria are met [[62]].

    Policy updates revise coverage stance to align with current evidence and regulatory guidance. Pharmacogenetic panel testing, previously not medically necessary in the policy, was changed to a criteria-based approach consistent with LCD guidance for indications such as major depressive disorder and generalized anxiety disorder, with a minimum age requirement of 18 years and a requirement that the requested panel be a validated test demonstrating clinical validity via independent third-party evaluation (examples: MolDX, ECRI, Hayes, Optum Genomics, FDA) [[78],[79],[80]].

    Policy Revision History and Material Changes

    2023-03-01revision

    Semi-annual policy revision (03/23) — updated title to V1.2024, replaced 'coverage criteria' wording with 'criteria', added multiple single-gene tests (e.g., BCHE, CYP3A5, NAT2), and revised criteria language to 'being considered' or 'or is currently undergoing'.

    2023-10-01revision

    Continued updates (10/23) — multiple single-gene and panel criteria edited, definitions updated, and additional clarifications to drug lists and indications were made.

    2023-11-01revision
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyConcert Genetic Testing: Toxicology and Pharmacogenetics (Version B)
    Policy CodePolicy N/A
    Change TypeMaterial updates to criteria, additions to coding table, FDA guidance incorporation
    Effective DateN/A
    Next Review DateN/A
    Key ActionOrder pharmacogenetic panels only when member meets criteria (age ≥18, specified diagnosis/treatment context, and the panel has demonstrated clinical validity).
    SourceLink
    On This Page
    Coverage Criteria for Pharmacogenetic and Toxicology Genetic TestingCoding and Billing ReferencesProvider Actions, Authorization, and Documentation RequirementsDefinitions and Terms Used in This PolicyBackground, Clinical Guidance, and ReferencesPolicy Revision History and Material Changes
    Mental Health Panel (Exceltox Laboratories LLC): 81418
  1. PGX (PHD Laboratory LLC): 81418
  2. PGS SHORT COMP (PHD Laboratory LLC): 81418
  3. Sinochips PGx Comprehensive (Sinochips Kansas LLC): 81418
  4. Carolina Comprehensive PGx (Carolina Diagnostics Lab): 81418
  5. COR120 - Comprehensive Pharmacogenetic Test (Quantigen LLC): 81418
  6. PCL PGX+ Comprehensive Report (Patients Choice Laboratories of Indiana, LLC): 81418
  7. PharmGx Comprehensive PGx Panel (Dxome CLIA Laboratory, Inc): 81418
  8. PsychPainMakers Panel (Genemarkers): 81418
  9. PredictScript Poly (Phenomics Health Inc): 81418
  10. PredictScriptCNS (Phenomics Health Inc): 81418
  11. Warfarin sensitivity multigene panel - authorization criteria

    Multigene panel analysis for warfarin sensitivity requires prior authorization and is considered medically necessary only when the member/enrollee is being considered for or is undergoing treatment with warfarin AND the member has not reached a therapeutic dose. Additionally, clinical indications for coverage include prophylaxis and treatment of venous thrombosis or pulmonary embolism; prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement; or a history of previous myocardial infarction. Multigene panels used for this indication must demonstrate clinical validity for the genes included.

    • Prior authorization required for warfarin sensitivity multigene panels when used for warfarin therapy guidance.
    • Panels must be limited to relevant genes and demonstrate clinical validity via independent evaluation.
    Prior Authorization

    BCHE variant analysis - authorization criteria

    BCHE variant analysis to determine drug metabolizer status is considered medically necessary when the member/enrollee is being considered for or is currently undergoing treatment with mivacurium (e.g., Mivacron) or succinylcholine (e.g., Anectine, Suxamethonium). BCHE testing for other indications is not supported by current evidence.

    • Prior authorization may be required per plan rules when BCHE testing is ordered for mivacurium or succinylcholine exposure.
    • Testing for BCHE for indications outside those listed is not supported and may be denied.
    Denial Risk

    General denial/limited coverage for other single-gene PGx tests — not supported by current evidence

    Current evidence does not support single-gene pharmacogenetic testing for many other genes (including, but not limited to, COMT, CYP1A2, KIF6, OPRM1, TYMS) to determine drug metabolizer status. Such tests are generally considered not medically necessary and may be denied or have limited coverage.

    • Examples of single-gene tests not supported: COMT (0032U, 81479); CYP1A2 (0031U, 81479); KIF6 (81479); OPRM1 (81479); TYMS (81479).
    • Providers should confirm plan-specific coverage before ordering these tests; claims may be denied if criteria are not met.
    Documentation Required

    Prior authorization / criteria wording changes — 'being considered' or 'or is currently undergoing' language updates

    Policy criteria language has been updated to clarify prior authorization and clinical-criteria statements. Wording such as "being considered for" or "is currently undergoing" treatment has been added across applicable criteria to better reflect clinical practice and authorization review. Providers should ensure documentation reflects whether a member is being considered for or is currently undergoing the relevant therapy when submitting authorization requests.

    • Authorization requests must document whether the patient is being considered for or is currently undergoing the specified treatment.
    • Plan-level prior authorization requirements remain in effect; follow payer-specific submission processes.
    Note

    Use of Clinical Policy in Coverage Decisions — policy guidance does not guarantee payment and is plan-dependent

    This clinical policy is guidance to assist in coverage determinations and does not guarantee payment. Coverage and payment decisions are subject to the member’s benefit plan, contract terms, and applicable state and federal requirements. Providers remain responsible for exercising professional judgment and for documenting medical necessity when submitting claims or prior authorization requests. When state Medicaid or Medicare requirements conflict with this policy, those requirements take precedence.

    • Policy guidance does not guarantee payment — check the member’s benefit documents for coverage limits and exclusions.
    • For Medicaid and Medicare members, applicable state and federal rules, NCDs, and LCDs take precedence over this policy.
    This clinical policy provides guidance on medical necessity to assist coverage determinations but does not guarantee payment.
    Provider judgmentProviders must exercise professional judgment; policy is not medical advice and does not dictate care.
    Warfarin sensitivity multigene panel
    DefinitionWarfarin sensitivity multigene panel: Multigene panel analysis to determine drug metabolizer status for warfarin sensitivity.
    Medical necessity triggersMedically necessary when member is being considered for or is undergoing warfarin therapy AND has not reached a therapeutic dose, or when undergoing prophylaxis/treatment for venous thrombosis/PE, thromboembolic complications of AF/valve replacement, or has prior MI.
    LimitationsCurrent evidence does not support multigene panel analysis for warfarin sensitivity for all other indications.
    Drug metabolizer status testing (variant analysis)
    DefinitionDrug metabolizer status testing: Variant analysis performed to determine an individual’s metabolizer phenotype for specific drugs (e.g., BCHE for mivacurium/succinylcholine).
    Indication exampleBCHE variant analysis is considered medically necessary when member is being considered for or currently undergoing treatment with mivacurium or succinylcholine.
    Evidence limitationCurrent evidence does not support variant analysis for other indications beyond specified drug-linked uses.
    Therapeutic dose (warfarin)
    DefinitionTherapeutic dose (warfarin): Clinical state in which a patient has reached the dose of warfarin that achieves the intended anticoagulation effect (used as a trigger for panel testing when not yet reached).
    Testing triggerMultigene warfarin panel is indicated when the member has not reached a therapeutic dose of warfarin and other clinical criteria are met.
    Clinical contextAlternative triggers include prophylaxis/treatment for venous thrombosis/PE, thromboembolic complications of AF/valve replacement, or history of MI.
    Pharmacogenomic test indication (CMS MolDX)
    CMS/MolDX guidance quotePGx tests are indicated when medications are being considered or administered and there is a known clinically actionable gene-drug interaction (per CMS/MolDX guidance cited in policy).
    Practical implicationTests should be ordered when the medication is medically necessary, appropriate, and has a demonstrated clinically actionable gene-drug interaction.
    Reference usagePolicy aligns PGx test indications with CMS/MolDX and FDA Table of Pharmacogenetic Associations recommendations.
    Clinical validity
    DefinitionClinical validity: the accuracy with which a test identifies a particular clinical condition, encompassing sensitivity, specificity, positive predictive value, and negative predictive value.
    SourceDefined per NIH-DOE Task Force on Genetic Testing as cited in the policy.
    RelevancePanel tests must demonstrate clinical validity via independent evaluation to meet coverage criteria.
    Policy criteria wording changes
    Wording changeCriteria language revised to refer to members 'being considered' for or 'or is currently undergoing' therapy/testing across multiple gene variant analyses.
    Terminology updatePolicy replaced phrasing 'coverage criteria' with 'criteria' throughout the document for consistency.
    Effect on indicationsUpdates clarified eligibility statements across single-gene and panel criteria to align with current evidence and coding updates.
    Definitions and single-gene criteria updates
    Genes updatedMultiple single-gene variant analyses updated, including UGT1A1, UGT2B17, VKORC1, DPYD, HLA-B*15:02, HLA-B*57:01, NAT2, TPMT, NUDT15, CYP family genes (e.g., CYP2C19, CYP2D6, CYP3A5, CYP4F2).
    Criteria editsChanges include added or clarified indications, addition of commonly prescribed drug names/brands, and reformatting for clarity.
    Coding updatesCPT codes were added and example tests updated in the Policy Reference Table concurrent with these definition changes.
    Pharmacogenetic panel testing definition and required validity
    Panel validity requirementPharmacogenetic panels must demonstrate proven clinical validity via independent evaluation from a recognized third-party source (e.g., MolDX, ECRI, Hayes, Optum Genomics, FDA).
    Named medically necessary panelsPolicy added specific panels to the medically necessary list when criteria are met (examples include Focused Pharm Panel, Tempus nP, Mental Health Panel, PGS SHORT COMP, Sinochips PGx, etc.).
    Coverage conditionalityPanel coverage requires meeting additional criteria such as age (>=18) and indication alignment (e.g., MDD or GAD) consistent with LCD-based guidance.
    Health Plan (definition)
    Health Plan definition'Health Plan' means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates.
    Policy roleThis clinical policy provides guidance on medical necessity to assist coverage decisions and does not constitute a contract or guarantee of payment.
    Regulatory precedenceCoverage decisions are subject to plan documents and applicable state and federal requirements; legal/regulatory requirements govern if discrepant.

    The revisions also add or clarify single-gene criteria and named tests: new criteria were created for HLA-A*02:01 (linked to therapies such as tebentafusp), and multiple single-gene entries (e.g., UGT1A1, UGT2B17, TPMT/NUDT15, VKORC1, CYP2C9) were updated to reflect FDA/NCCN recommendations and to include drug brand names or monitoring/dosing guidance where indicated [[78],[79],[80]].

    Specifically, FDA management recommendations underpin several of the coverage changes: warfarin-related genes (CYP2C9, CYP4F2, VKORC1) are cited to justify allowing small targeted panels for warfarin sensitivity when members have not reached a therapeutic dose or meet other clinical triggers, with dosing and INR monitoring emphasized [[62]]. TPMT/NUDT15 guidance from the FDA supports dose-reduction or alternative therapy recommendations for intermediate/poor metabolizers, which the policy incorporates into TPMT/NUDT15 criteria [[57]]. UGT1A1 evidence from the FDA informed reduced starting dose and enhanced monitoring recommendations for irinotecan and belinostat that are reflected in the updated UGT1A1 criteria [[59]].

    Overall, the material changes include addition of validated pharmacogenetic panels to the medically necessary list when criteria are met, expansion and clarification of single-gene indications tied to specific medications, and a requirement that panels demonstrate independent clinical validity — all intended to align coverage with available regulatory recommendations and clinical evidence while limiting unsupported single-gene analyses.

    Latest

    Revision (11/23) — added CPT codes 0423U, 0434U, 0437U, 0438U to the policy coding reference table and updated pharmacogenetic panel criteria and assorted single-gene definitions and indications (e.g., UGT1A1, UGT2B17, VKORC1, DPYD, HLA variants).

    2023-11-01coding_updateLatest

    Added new CPT/PLA codes 0423U, 0434U, 0437U, and 0438U to the policy coding reference table and incorporated them into panel test criteria references.